Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection

Annals of the Rheumatic Diseases

Volumn 69, Issue 7, 2010, Pages 1352-1355

  Vassilopoulos, Dimitrios ^a   Apostolopoulou, A ^a   Hadziyannis, E ^a   Papatheodoridis, G V ^a   Manolakopoulos, S ^a   Koskinas, J ^a   Manesis, E K ^a   Archimandritis, A I ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; ETANERCEPT; HEPATITIS B SURFACE ANTIBODY; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; STEROID; VIRUS DNA; ANTIRHEUMATIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CROHN DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LONG TERM CARE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; VACCINATION; VIRUS STRAIN; AGED; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; VIRUS ACTIVATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 77954991111     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.127233     Document Type: Article

References (18)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
2. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(Suppl):S156-65.
3. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9.
4. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36:1188-94.
5. Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009;36:2416-20.
6. Wendling D, Di Martino V, Prati C, et al. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009;76:308-11.
7. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008;38:208-17.
8. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:20-34.
9. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
11. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: Update 2009. http://www.aasld.org. (accessed 9 Dec 2009).
12. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34(Pt 1):617-24.
13. Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67(Suppl 3):iii2-25.
14. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121-9.
15. Vassilopoulos D, Manolakopoulos S. Rheumatic manifestations of hepatitis. Curr Opin Rheumatol 2010;22:91-6.
16. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-20.
17. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9.
18. Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179.